Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
He has published more than 100 research papers in several prestigious national and international journals
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
India has the second-largest number of adults with diabetes globally, after China
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Subscribe To Our Newsletter & Stay Updated
